ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer

ClinicalTrials.gov ID: NCT00959959

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00959959. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

ARMOR1: Phase 1, Open Label, Dose Escalation Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine whether TOK-001 is safe and shows biological effect in the treatment of castration resistant prostate cancer (CRPC).

Study identification

NCT ID: NCT00959959
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: LTN PHARMACEUTICALS, INC.; Industry
Enrollment: 49 participants

Conditions and interventions

Conditions

Prostate Cancer

Interventions

TOK-001 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Male
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 2009 (Type not available)
Primary completion: Aug 2011 (Actual)
Completion: Aug 2012 (Actual)
Last update posted: Sep 4, 2020

2009 – 2012

United States locations

U.S. sites: 8
U.S. states: 7
U.S. cities: 8

Facility	City	State	ZIP	Site status
UCLA	Los Angeles	California	90095	—
San Bernardino Urological Associates	San Bernardino	California	92404	—
Johns Hopkins Hospital	Baltimore	Maryland	21231	—
Dana Farber Cancer Institute	Boston	Massachusetts	02115	—
Comprehensive Cancer Centers of Nevada & US Oncology Research	Las Vegas	Nevada	89169	—
Roswell Park Cancer Institute	Buffalo	New York	14263	—
Greenville Hospital System University Medical Center	Greenville	South Carolina	29605	—
University of Washington/Seattle Cancer Care Alliance	Seattle	Washington	98136	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00959959, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 4, 2020 · Synced Nov 12, 2026